aTyr Pharma Inc
ATYR5.023USD
+0.323+6.87%
交易中 （美东）报价延迟15分钟
447.03M总市值
亏损市盈率 TTM
关于 aTyr Pharma Inc 公司
aTyr Pharma, Inc. 是一家临床阶段的生物技术公司。该公司正在利用情报将 tRNA 合成酶生物学转化为治疗纤维化和炎症的新疗法。其主要治疗候选药物是 efzofitimod，这是一种生物免疫调节剂，处于临床开发阶段，用于治疗间质性肺病 (ILD)，这是一组可导致肺部炎症和纤维化或瘢痕形成的免疫介导疾病。Efzofitimod 是一种 tRNA 合成酶衍生疗法，可通过神经纤毛蛋白-2 (NRP2) 选择性调节活化的髓系细胞，以在不抑制免疫的情况下解决异常炎症并防止纤维化进展。ATYR0101 是一种源自天冬氨酰-tRNA 合成酶 (DARS) 结构域的融合蛋白。ATYR0101 直接与潜伏转化生长因子 β 结合蛋白 1 (LTBP1) 结合，后者调节转化生长因子 β (TGFb)。其 ATYR0750 是一种源自丙氨酰-tRNA 合成酶 (AARS) 结构域的融合蛋白。
公司简介
公司代码ATYR
公司名称aTyr Pharma Inc
上市日期May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
员工数量56
证券类型Ordinary Share
年结日May 07
公司地址10240 Sorrento Valley Road
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92121
电话18587318389
网址https://www.atyrpharma.com/
公司代码ATYR
上市日期May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric S. Benevich
Mr. Eric S. Benevich
Independent Director
Independent Director
--
--
Ms. Nancy E. Denyes, J.D.
Ms. Nancy E. Denyes, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
股东类型
持股股东
占比
Investment Advisor
27.84%
Investment Advisor/Hedge Fund
20.75%
Hedge Fund
20.46%
Individual Investor
2.23%
Research Firm
1.92%
Pension Fund
0.20%
Bank and Trust
0.05%
Venture Capital
0.02%
Other
26.52%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
160
65.39M
73.47%
+2.57M
2025Q1
162
64.83M
72.99%
-691.51K
2024Q4
140
57.60M
68.66%
-6.81M
2024Q3
117
50.41M
67.53%
-11.03M
2024Q2
113
50.68M
74.24%
-3.06M
2024Q1
111
44.35M
66.05%
-8.23M
2023Q4
110
43.49M
75.20%
-5.05M
2023Q3
109
43.22M
76.15%
+288.84K
2023Q2
108
41.84M
78.83%
+2.15M
2023Q1
98
40.77M
78.21%
+15.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Federated Hermes Global Investment Management Corp.
14.67M
16.48%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
12.89M
14.49%
+796.10K
+6.58%
Mar 31, 2025
The Vanguard Group, Inc.
4.01M
4.5%
+401.81K
+11.15%
Mar 31, 2025
Octagon Capital Advisors LP
3.55M
3.99%
+2.65M
+294.67%
Mar 31, 2025
Point72 Asset Management, L.P.
2.84M
3.2%
-2.04M
-41.76%
Mar 31, 2025
Tikvah Management LLC
2.46M
2.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.73M
1.95%
+945.24K
+119.98%
Mar 31, 2025
Woodline Partners LP
1.68M
1.89%
-1.41K
-0.08%
Mar 31, 2025
UBS Financial Services, Inc.
1.61M
1.81%
+1.38M
+600.20%
Mar 31, 2025
Millennium Management LLC
1.60M
1.8%
+1.23M
+334.53%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
iShares Micro-Cap ETF
0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0%
查看更多
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.42%
iShares Micro-Cap ETF
占比0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.03%
ProShares Hedge Replication ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.02%
iShares Russell 2000 Growth ETF
占比0.02%
Global X Russell 2000 ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.02%
iShares Russell 2000 ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
